<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 12</script></head><body class="s12"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal active"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.nextSlide()" class="page-next"></div><div onclick="iRep.go(6)" class="page-prev"></div></div><article><h1>Pradaxa<sup>®</sup>: The only NOAC with immediate <br/> reversal in rare emergency situations<sup>1–5</sup></h1><div class="big-image"></div><div class="small-image"></div><p class="notes"><strong>Praxbind<sup>®</sup></strong> is a <strong>specific reversal agent</strong> for dabigatran and is indicated in adult patients treated<br/> with <strong>Pradaxa<sup>®</sup></strong> (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:<sup>1</sup></p><div class="bullets notes"><span>&bull; For emergency surgery/urgent procedures</span><span class="last">&bull; In life-threatening or uncontrolled bleeding</span></div></article><div class="overlay"></div><div class="sidebar"><ul><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"><b>References: 1.</b> Boehringer Ingelheim. Pradaxa<sup>®</sup> Summary of Product Characteristics. <strong>2.</strong> Boehringer Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.
 <strong>3.</strong> Schiele F <br/>
 <em>et al. Blood</em> 2013;121(18):3554–3562. <strong>4.</strong> Sarich TC <em>et al. Am Heart J</em> 2015;169(6):751–757. <strong>5.</strong> Pollack CV <em>et al. N Engl J Med</em> 2015;373(6):511–520.
 <strong>6.</strong> Portola<br/> Pharmaceuticals, Inc., Corporate Update, January 2016, available at: http://investors.portola.comlphoenix.zhtml?c=198136&p=iroI-irhome. Accessed on 03/02/2016.</div></div></div></div></div></body></html>